Viridian Therapeutics, Inc. (VRDN)
Market Cap | 933.93M |
Revenue (ttm) | 347,000 |
Net Income (ttm) | -216.66M |
Shares Out | 52.59M |
EPS (ttm) | -5.14 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 832,301 |
Open | 17.78 |
Previous Close | 17.76 |
Day's Range | 17.78 - 18.98 |
52-Week Range | 10.93 - 39.00 |
Beta | 1.05 |
Analysts | Strong Buy |
Price Target | 39.45 (+112.21%) |
Earnings Date | Nov 13, 2023 |
About VRDN
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeut... [Read more]
Financial Performance
In 2022, VRDN's revenue was $1.77 million, a decrease of -40.20% compared to the previous year's $2.96 million. Losses were -$129.87 million, 63.5% more than in 2021.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for VRDN stock is "Strong Buy." The 12-month stock price forecast is $39.45, which is an increase of 112.21% from the latest price.
News

Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...

Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...

Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therap...

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian The...

Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therap...

Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class med...

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therape...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therapeu...

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therapeu...

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 14, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therapeu...

Viridian stock falls more than 15% after drug study update
Shares of Viridian Therapeutics Inc. VRDN, +5.06% fell in the extended session Monday after the biotech drug maker said it was making changes to its study design for a chronic thyroid eye disease ther...

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class med...

Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
- Topline data from proof-of-concept study of VRDN-001 in patients with chronic thyroid eye disease (TED) are expected in June/July 2023 -

Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
- Partnership to support one of the Company's preclinical programs outside of thyroid eye disease (TED) - WALTHAM, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a...

Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023
WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for ser...

UPDATE – Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
- Presentations to cover updated clinical and preclinical data on pipeline candidates in Company's thyroid eye disease program -